All In Biotech

Drug Trial Radar · NCT07804901

Asciminib Frontline Risk Adapted

Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Jan 1, 2027

Primary completion

Dec 31, 2030

Study completion Jun 30, 2031

Sponsor

Lead sponsor
Prof. Dr. med. Andreas HochhausAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, prospective, non-randomized but stratified interventional phase II study of newly diagnosed CML patients in chronic phase. All patients will be treated with asciminib 80 mg QD. Patients with unfavorable risk factors will commence dasatinib 80 mg 5 days/week 4 weeks after start of asciminib. The study will be conducted in Germany.

Conditions

  • Chronic Myeloid Leukemia (CML)

Interventions

  • Dasatinib 80mg QD (5 days per week)Drug

    Patients with unfavorable risk factors will commence dasatinib 80 mg 5 days/week 4 weeks after start of asciminib.

  • Standarc of CareDrug

    Asciminib 80mg QD ist the usual standard of care therapy for CML

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of MMR at 12 monthsTime frame: 12 months after start of therapy

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Universitätsklinikum Jena

    Jena, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.